Pyxis Oncology announced its Q3 2026 financial results and progress on its cancer drug micvotabart pelidotin (MICVO). Updated Phase 1 data showed promising efficacy and safety in treating recurrent/metastatic head and neck cancer. The company plans to start a global Phase 3 trial in mid-2027 after FDA dose feedback expected in early 2027. Pyxis also raised $110 million in a recent public offering, funding operations into mid-2028, and will present new clinical data at upcoming conferences.
Pyxis Oncology's Q3 2026 financial results and clinical progress provide context for readers following healthcare developments. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 05, 2026 19:01 WIB: out of 150 priced US health-sector stocks, 94 rose and 48 fell today. Notable movers include MESO (Mesoblast Limited) at USD 14.79 with a 3.50% increase and a typical hold time of 16 days, EW (Edwards Lifesciences Corporation) at USD 102.74 up 3.39% with Pluang order activity showing 85% sell and 15% buy, and LFST (LifeStance Health Group Inc.) at USD 14.67 rising 3.24% with a typical hold time of 13 days.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
